Format

Send to

Choose Destination
Curr Opin Mol Ther. 2005 Aug;7(4):366-75.

Technology evaluation: NV-1020, MediGene.

Author information

1
Academy of Sciences of the Czech Republic, Institute of Molecular Genetics, Flemingovo nam 2, Prague 6, CZ-16637. reinis@img.cas.cz

Abstract

NV-1020 is a recombinant oncolytic HSV-based virus, in development by MediGene (formerly NeuroVir) for the potential treatment of cancer. The therapy is currently undergoing phase II clinical trials.

PMID:
16121703
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center